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Citrullination is a post-translational modification of arginine that commonly occurs in
inflammatory tissues. Because T-cell receptor (TCR) signal quantity and quality can regu-
late T-cell differentiation, citrullination within a T-cell epitope has potential implications
for T-cell effector function. Here, we investigated how citrullination of an immunedomi-
nant T-cell epitope affected Th17 development. Murine naı¨ve CD4+ T cells with a trans-
genic TCR recognising p89-103 of the G1 domain of aggrecan (agg) were co-cultured with
syngeneic bone marrow-derived dendritic cells (BMDC) presenting the native or citrulli-
nated peptides. In the presence of pro-Th17 cytokines, the peptide citrullinated on residue
93 (R93Cit) significantly enhanced Th17 development whilst impairing the Th2 response,
compared to the native peptide. T cells responding to R93Cit produced less IL-2, expressed
lower levels of the IL-2 receptor subunit CD25, and showed reduced STAT5 phosphoryl-
ation, whilst STAT3 activation was unaltered. IL-2 blockade in native p89-103-primed
T cells enhanced the phosphorylated STAT3/STAT5 ratio, and concomitantly enhanced
Th17 development. Our data illustrate how a post-translational modification of a TCR
contact point may promote Th17 development by altering the balance between STAT5
and STAT3 activation in responding T cells, and provide new insight into how protein
citrullination may influence effector Th-cell development in inflammatory disorders.
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Introduction
Th17 cells are a subset of CD4+ T cells defined by production of the
signature cytokine IL-17A (hereafter referred to as IL-17) [1–3].
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Along with IL-17, these cells are critical producers of IL-17F, IL-
21, IL-22 and a source of T-cell-derived GM-CSF [4, 5]. These
cells provide an important defense against fungal infections and
invading extracellular bacteria [6–8]. However, a dysregulated
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Th17 response can mediate pathogenesis in autoimmune diseases
such as psoriasis, multiple sclerosis, and rheumatoid arthritis (RA)
[9–11].
It has been well characterized that the cytokine milieu present
during the activation of a naive T cell is important in determin-
ing which subset predominates in the adaptive immune response
[12–14]. Classically TGF-β and IL-6 are thought to induce the
generation of Th17 cells, which can be further supported by
TNF, IL-1β, and IL-23 [15, 16]. However, this qualitative view
of Th responses negates the influence of the T-cell receptor (TCR)
on the fate of precursor cells [17–19]. Seminal studies in the
mid-1990s demonstrated that the Th1-Th2 balance can be pro-
foundly altered by the density or TCR affinity of the priming
peptide [20, 21]. Further work has shown a preference for a
low density of a high affinity peptide for optimal Treg genera-
tion [22]. Indeed, our studies have demonstrated that a lower
T-cell activation signal delivered through CD3/CD28 antibodies
leads to enhanced generation of human and mouse Th17 cells
when compared to a strong CD3/CD28 -mediated activation signal
[23].
There are over a hundred distinct forms of post-translational
amino acid modifications, which can introduce diversity into pro-
teins [24]. Of these the most commonly associated with autoim-
mune diseases is citrullination, which occurs after the deimi-
nation of an arginine to citrulline (Cit) [25]. The conversion
is catalyzed by a family of calcium-dependent enzymes termed
peptidylarginine-deiminases (PADIs), of which PADI2 and PADI4
are upregulated in inflammation [26]. Citrullinated proteins are
more arthritogenic in experimental models of arthritis in rodents
[27, 28]. In humans, autoantibodies against citrullinated anti-
gens, known as anti-citrullinated protein antibodies (ACPA), have
been shown to be a marker of aggressive arthritis, predictive
of erosive disease, and highly specific to RA [29, 30]. T cells
reacting to citrullinated self-epitopes releasing pro-inflammatory
cytokines including IL-17, IL-6, and/or IFN-γ have been found
in RA patients, suggesting a pathogenic role for these T cells
[31–33].
Here we investigated whether citrullination of a TCR epitope
altered Th17 development. To this aim, we used TCR-transgenic
(TCRtg) murine CD4+ T-cells expressing a TCR specific to an
immunodominant peptide derived from the G1 domain of pro-
teoglycan aggrecan (agg), p89-103. The native form of this pep-
tide contains two arginines, one of which is a putative TCR
contact point (R93) [34]. We found that the R93-citrullinated
peptide (R93Cit) induced higher levels of Th17-cell polariza-
tion from na¨ıve aggTCRtg CD4+ T-cells than the native p89-
103 peptide, while impairing Th2 development. Furthermore,
R93Cit induced lower levels of IL-2 and CD25 expression, lead-
ing to an enhanced ratio of STAT3 to STAT5 phosphorylation,
thus linking the intensity of TCR-dependent T-cell activation to
the pathway critical for Th17 generation. We propose that the
degree of TCR-mediated T-cell activation influences effector func-
tion through controlling the balance between STAT5 and STAT3
activation.
Results
Citrullination of the putative TCR contact residue R93
results in a subagonist response
We first addressed the question of how citrullination of peptide
p89-103 of the G1 domain of aggrecan affected the magnitude of
na¨ıve CD4+ T-cell responses. The native aggrecan peptide contains
two arginines offering three potential citrullinated forms (R93Cit,
R95Cit, and R93-95Cit). R93 is an accepted TCR contact point
whereas R95 is a putative MHC class II contact point [34]. We
assessed the ability of LPS-matured BMDC to induce prolifera-
tion of na¨ıve aggTCRtg T cells at a high, fixed peptide concentra-
tion (2μM) over a period of 7 days. Citrullination of the putative
TCR contact point R93 (R93Cit) resulted in a subagonist response
with slower proliferation kinetics as compared to the native pep-
tide p89-103, although R93Cit-stimulated T cells displayed similar
levels of proliferation as p89-103-stimulated T cells at later time
points (days 5 and 7; Fig. 1A). In contrast, peptides in which the
MHCII contact point R95 had been citrullinated (R95Cit and R93-
95Cit) were not capable of inducing T-cell expansion above levels
of the negative control peptide. To further clarify the differing
potential of the native and R93Cit peptide to induce T-cell pro-
liferation, the dose of both peptides was titrated. After 72h, p89-
103 showed significantly enhanced proliferation when compared
to R93Cit over a wide dose range (p < 0.01) (Fig. 1B). Moreover,
expression of the early activation marker CD69 was also signifi-
cantly higher in those activated with native p89-103 than R93Cit
(Fig. 1C/D). Thus, the data show that citrullination of the TCR
contact residue results in a subagonist response whereas modi-
fication of the putative MHCII binding residue completely abro-
gates the T-cell response. Therefore, further experiments focused
on comparing the native and the R93Cit peptide only.
Citrullination of the R93 residue favors Th17 cell
generation while impairing Th2 development
Next, we assessed the effect of citrullination of the T-cell con-
tact residue R93 on the qualitative nature of the CD4+ T-cell
response. We used a two-stage co-culture system with na¨ıve
T cells primed by either native p89-103 or R93Cit across a
range of concentrations in the absence or presence of pro-
Th17 cytokines. After 5 days, when proliferative responses to
both peptides had reached the lag phase, cultures were normal-
ized for cell number and re-stimulated with fresh BMDC and a
fixed dose of native peptide; cytokines in supernatants were mea-
sured after 48 h. This experimental set up ensured that all sec-
ondary cultures received a signal of equivalent strength, allowing
comparison of how different T-cell priming conditions affected
their polarization. The two peptides led to significant differences
in the priming for both IL-17 and IL-4 (Fig. 2; for representative
flow cytometry plots see Supporting Information Fig. 1). In the
presence of pro-Th17 cytokines, IL-17 production was promoted at
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Figure 1. Citrullination of a T-cell epi-
tope results in reduced T-cell prolifera-
tion.Naı¨ve aggTCRtgT cells (from5/4E8-
TCR-Tg BALB/c mice) were co-cultured
with mature syngeneic BMDC together
with either native agg peptide p89-103,
peptides citrullinated at either position
93 (R93Cit), 95 (R95Cit) or both (R93-
95Cit), or F1P3 negative control pep-
tide for 3, 5, or 7 days before being
pulsed with 3H-Thymidine. (A) Prolifer-
ation of aggTCRtg T-cells. (B) Dose titra-
tions of both p89-103 and R93Cit; pro-
liferation was measured after 3 days.
(C) CD69 expression on aggTCRtg
T-cells after 24 h was determined by
flow cytometry. (D) Representative his-
togram of CD69 expression. Data shown
as the mean + standard error of the
mean (SEM = SD/3) of three indepen-
dent experiments—the mean of three
technical replicates from one mouse
per experiment; p-values were calcu-
lated using two-way ANOVA; *p<0.05,
**p<0.01, ***p<0.001.
either a low dose of the native peptide or a high dose of the R93Cit
peptide (Fig. 2A, upper left panel). These data are consistent with
the concept that TCR-mediated signal strength is regulated by both
peptide affinity and density. Notably, IL-17 production was not
supported by either peptide in the absence of pro-Th17 cytokines
(Fig. 2A; lower left panel). In contrast, IL-4 showed a posi-
tive correlation with increasing concentration of native peptide,
but with significantly lower levels induced by the citrullinated
form in either the absence or presence of pro-Th17 cytokines
(Fig. 2A). IFN-γ production did not vary significantly over the
range of concentrations of R93Cit tested. In contrast, a positive
correlation between IFN-γ production and peptide concentration
was observed in those T cells primed with native peptide.
We also determined the proportion of cytokine-producing
CD4+ T cells by intracellular cytokine staining. A similar picture
emerged with the R93Cit peptide inducing a higher percentage
of IL-17+ cells and significantly fewer IL-4+ cells at the higher
peptide doses, whereas the proportion of IFN-γ+ cells only varied
slightly across the peptide dose range and between the two
peptides (Fig. 2B). Consistent with the ELISA data, promotion
of IL-17-producing T cells by a high dose of R93Cit required
a pro-Th17 cytokine environment during T-cell priming. These
observations are supported by a significantly enhanced expression
of the Th17-related transcription factor ROR-γT induced by the
2μM dose of R93Cit, as compared to native peptide (Fig. 3).
Thus, our data demonstrate that while an appropriate cytokine
milieu is a contributing factor for Th17 development, a lower
TCR-mediated activation signal at a high peptide density signif-
icantly polarizes na¨ıve T cells toward a Th17 phenotype while
inhibiting Th2 development.
Production of other pathogenic Th17 cytokines is
enhanced by citrullination of the R93 residue
IL-17 is an important mediator of inflammation with a role in
several chronic diseases, and yet recent studies have shown that
it is not the absolute determinant of pathogenicity. Therefore,
we sought to assess production of associated cytokines GM-CSF
and IL-22 known to define Th17 pathogenesis in vivo [35–37].
Naive T-cell/BMDC co-cultures were established in the presence
of pro-Th17 cytokines and supernatants of secondary co-cultures
analyzed by ELISA. At the 2μMdose, the R93Cit peptide promoted
significantly more GM-CSF and IL-22 production than the native
peptide (Fig. 4). We also measured IL-10, but levels remained
below the detection limit of the ELISA (data not shown). Thus, a
reduction in TCR-mediated signal strength through citrullination
of a T-cell epitope can lead to enhanced production of not only
IL-17 but also Th17-related cytokines.
Low IL-2 production in response to R93Cit peptide
facilitates the Th17 response
In order to understand the mechanism by which the R93 citrulli-
nated epitope promotes pathogenic Th17 responses, we aimed to
assess the role of factors downstream of TCR stimulation. One of
the major products of TCR stimulation is IL-2, known to be a nega-
tive regulator of IL-17 release [38]. We therefore sought to define
both the levels of IL-2 and the expression of CD25 (the high affin-
ity component of the IL-2R) induced by either p89-103 or R93Cit.
IL-2 production induced by the agonistic p89-103 peptide was
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. Citrullinated aggrecan peptide favor-
favors Th17 cells while impairing Th2 devel-
opment. Naı¨ve aggTCRtg T-cells (from 5/4E8-
TCR-Tg BALB/c mice) were co-cultured with
mature syngeneic BMDC with either p89-103 or
R93Cit in the presence or absence of pro-Th17
cytokines (IL-1β/IL-6/IL-23/TGFβ). (A) Secondary
cultures with p89-103 and mature BMDC were
established before supernatants were collected
and IL-17, IL-4, and IFN-γ analyzed by ELISA.
(B) Intracellular cytokine production by CD4+ T-
cells was assessed by flow cytometry. The dot-
ted line indicates values obtained from cultures
primed with the control peptide F1P3, which is
not recognized by the 5/4E8 TCR. Data shown
as the mean + standard error of the mean (SEM
= SD/3) of three independent experiments—
the mean of three technical replicates from one
mouse per experiment; p-values were calcu-
lated using two-way ANOVA; *p<0.05, **p<0.01,
***p<0.001.
significantly greater during the first 72 h of culture, as com-
pared to levels induced by the subagonist R93Cit peptide (Fig.
5A). The peak release of IL-2 in response to R93Cit stimula-
tion was also reduced and delayed compared to native p89-103
stimulation. We also sought to assess the extent to which these
T-cells could respond to IL-2 and we therefore examined the
degree of CD25 expression. Analysis by flow cytometry showed
that induction of CD25 by R93Cit was substantially and signif-
icantly reduced compared to the native peptide p89-103 (Fig.
5B; for representative flow plots see Supporting Information
Fig. 2).
Given the distinct differences in both IL-2 production and
the level of CD25 receptor expression by native p89-103- and
R93Cit- stimulated CD4 T-cells, we wished to clarify whether
alterations to the IL-2 signaling pathway affected Th17 prim-
ing. Despite expressing less CD25, addition of rIL-2 during prim-
ing of T cells with R93Cit significantly reduced the production
of IL-17 in secondary cultures (Fig. 5C). Conversely, blocking of
endogenous IL-2 in p89-103-stimulated cultures enhanced Th17
development (Fig. 5D). Our data suggest that citrullination of R93
in the epitope leads to a reduction in the IL-2-mediated antago-
nistic effects on Th17 development.
STAT3:STAT5 ratio is changed in response to the
R93Cit peptide
The balance between STAT3 and STAT5 is thought to be crit-
ical in regulating IL-17 production through competition at the
il17a locus, with STAT3 promoting and STAT5 inhibiting il-17
transcription, respectively [39]. Our aim was to assess if the
differences in the IL-2 pathway that we observed between native
and R93Cit peptide-stimulated T cells would be reflected by
changes to the pSTAT3:pSTAT5 balance in these cells. To assess
the degree of STAT3(Y705) and STAT5(Y694) phosphorylation
we activated BMDC/na¨ıve aggTCRtg T-cell primary cultures with
peptides in the presence of pro-Th17 cytokines and determined
phosphorylation of STAT3 and 5 by Phosflow over 5 days (Fig. 6A,
B; for representative flow plots see Supporting Information Fig. 3).
Interestingly, we found that in both the native and R93Cit peptide-
stimulated cultures similar levels of STAT3 phosphorylation were
found, exceeding those found in the control irrelevant peptide-
stimulated cultures (Fig. 6A). Induction of STAT3 phosphorylation
could not be attributed to the presence of exogenous pro-Th17
cytokines IL-6 and IL-23 as a similar pattern of STAT3 phosphory-
lation was observed in T cells stimulated in the absence of these
C© 2016 The Authors. European Journal of Immunology published by
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Figure 3. Citrullinated aggrecan peptide enhances ROR-γT expression. Naı¨ve aggTCRtg T-cells (from 5/4E8-TCR-Tg BALB/c mice) were co-cultured
with mature syngeneic BMDC with either p89-103 or R93Cit in the presence of pro-Th17 cytokines (IL-1β/IL-6/IL-23/TGFβ). F1P3 (derived from
Yersinia pestis capsular protein), an Ad binding peptide, was included as a negative control peptide unable to induce proliferation of 5/E4 T cells.
ROR-γT expression and IL-17 production by CD4+ T cells were assessed by flow cytometry. (A) Representative contour plots of three independent
experiments with a single mouse per experiment are shown. (B) Percentage of ROR-γT-positive cells. Data shown as the mean + standard error
of the mean (SEM = SD/3) of three independent experiments—the mean of three technical replicates from one mouse per experiment; p-values
were calculated using two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001.
exogenous cytokines, albeit with lower overall levels of STAT3
phosphorylation (data not shown). In contrast, T cells stimulated
with p89-103 gained a higher level of pSTAT5 when compared
to R93Cit-stimulated T cells: this difference was most pronounced
and significant at the 24h time point (Fig. 6B). As a result, the
pSTAT3:pSTAT5 ratio in R93Cit-stimulated T cells was signifi-
cantly higher than in p89-103-stimulated T cells at the 24-h time
point (Fig. 6E).
To confirm that the IL-2 pathway was responsible for the lower
pSTAT3:pSTAT5 ratio in p89-103 stimulated T cells, endogenous
IL-2 was blocked by anti-IL-2 antibody in p89-103-stimulated
DC/na¨ıve T cell cultures. We found that anti-IL-2 reduced pSTAT5
activation to background levels (Fig. 6D). A reduction in pSTAT3
was also observed but the downregulation was much less pro-
nounced (Fig. 6C). The balance of pSTAT3 relative to pSTAT5 was
shifted in favor of STAT3, leading to a higher pSTAT3:pSTAT5
ratio (Fig. 6F) and explaining why anti-IL-2 enhanced the
Th17 response (Fig. 5D). In summary, our data are consistent
with the notion that the lower affinity of the R93Cit peptide
supports lower IL-2 production and, at early time points, a higher
pSTAT3:pSTAT5 ratio, which promotes development of a Th17
phenotype.
Discussion
Citrullination is a common post-translational protein modification
that occurs during inflammation, but how this affects develop-
ment of effector T-cell responses is poorly understood. Here we
show that citrullination of the putative TCR contact point (R93)
of the arthritogenic aggrecan-derived peptide p89-103 has a pro-
found effect on na¨ıve CD4+ T-cell development. Compared to the
native peptide, the R93Cit peptide significantly enhanced the Th17
response, reduced IL-4-production, while maintaining support for
IFN-γ secretion at even very low peptide doses. The data suggest
that citrullination of the R93 TCR contact point reduces TCR sig-
naling intensity, leading to lower levels of IL-2 secretion and IL-2
receptor (CD25) expression. This, in turn, leads to lower levels
of STAT5 phosphorylation, thereby reducing the inhibitory action
of STAT5 on Th17 development. However, the pro-Th17 effect of
R93Cit was only evident in the presence of pro-Th17 cytokines,
most likely because these cytokines were required for efficient
activation of the Th17-promoting STAT3 pathway. Our data show
for the first time how citrullination of a T-cell epitope can lead to
enhanced Th17 differentiation, and also emphasize how the con-
certed actions of TCR- and cytokine-mediated signaling determine
effector T-cell development.
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Figure 4. Production of GM-CSF and IL-22 is
enhanced by peptide citrullination. Naı¨ve aggTCRtg
T cells (from 5/4E8-TCR-Tg BALB/c mice) were co-
cultured with mature syngeneic BMDC and either
p89-103 or R93Cit in the presence of pro-Th17
cytokines (IL-1β/IL-6/IL-23/TGFβ). Secondary cul-
tures stimulated with p89-103 and mature BMDC
were established before supernatantswere collected
and GM-CSF (A) or IL-22 (B) measured by ELISA. Data
shown as the mean + standard error of the mean
(SEM = SD/3) of three independent experiments—
the mean of two technical replicates from one
mouse per experiment; p-values were calculated
using two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001.
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Figure 5. Reduced IL-2 levels in citrullinated aggre-
can peptide stimulated T cells promote Th17 devel-
opment. Co-cultures of naı¨ve aggTCRtg T-cells (from
5/4E8-TCR-Tg BALB/c mice) and mature syngeneic
BMDC were activated with either p89-103 or R93Cit
in the presence of pro-Th17 cytokines (IL-1β/IL-6/IL-
23/TGFβ). Primary supernatants were collected and
(A) IL-2 levels weremeasured by ELISA at designated
time points and (B) the expression levels of CD25 on
CD4+ T-cells after 5 days were determined by flow
cytometry. Control: negative control peptide F1P3.
The role of IL-2 in Th17 skewing was assessed by
activation of naı¨ve T cells with R93Cit in the pres-
ence or absence of rhIL-2 (C) or p89-103 in the pres-
ence or absence of neutralizing anti-IL-2 antibody
(D) for 5 days before secondary cultureswith p89-103
and mature BMDC were established. Levels of IL-17
were analyzed by ELISA. Data shown as the mean +
standard error of the mean (SEM = SD/3) of three
independent experiments—the mean of three tech-
nical replicates from one mouse per experiment;
p-values were calculated using two-way ANOVA;
*p<0.05, **p<0.01, ***p<0.001.
In this study we chose the agg-derived p89-103 peptide
because it contains two arginines at two crucial positions: R93
(p2), which is a putative TCR contact point and R95 (p4), a
proposed MHCII anchor residue [34, 40]. Within polypeptides
arginine is a positive charged residue, but citrullination will
change the net charge from positive to neutral. Therefore,
alterations in the TCR- and/or MHCII-binding capacity of the
citrullinated form of the p89-103 peptide can be expected. Indeed,
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Figure 6. STAT3:STAT5 balance is influenced by peptide citrullination. Naı¨ve aggTCRtg T cells (from 5/4E8-TCR-Tg BALB/c mice) were co-cultured
with either p89-103 or R93Cit and mature syngeneic BMDC in the presence of pro-Th17 cytokines (IL-1β/IL-6/IL-23/TGFβ). Levels of pSTAT3(Y705)
and pSTAT5(Y694) in CD4+ T cells were determined by Phosflow after 24, 48, 72, 96, and 120 h. (A, B) MFIs of pSTAT3 and pSTAT5. (C, D), The effect
of IL-2 blockade was assessed using naı¨ve T cells activated with p89-103 and syngeneic BMDC in the presence of either isotype control or IL-2
blocking antibody. (E, F) The ratio of pSTAT3:pSTAT5 MFIs was determined for each time point. Data shown as the mean + standard error of the
mean (SEM = SD/3) of three independent experiments—the mean of three technical replicates from one mouse per experiment; p-values were
calculated using two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001. In plots A and B, *indicates significant differences between p89-103 and R93Cit,
and ˆindicates significant differences between the control and both p89-103 and R93Cit.
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2016. 46: 1633–1643 Adaptive immunity 1639
citrullination of the R93 residue creates a subagonistic peptide
in terms of initiating proliferation, IL-2 production and CD25/69
expression of responding aggTCRtg T-cells (Figs. 1 and 5). These
data are most likely explained by an altered affinity of the R93Cit
peptide for the aggTCR, because the binding of this peptide to
MHCII (I-Ad) has been reported to be similar to binding of the
native peptide [41]. Citrullination of the R95 residue, on the
other hand, resulted in a ‘null-peptide’ that did not induce any
significant T-cell proliferation above the background (Fig. 1).
Therefore, further work focused on the R93Cit peptide.
The regulatory role of TCR signaling has been widely docu-
mented with regards to Th1- and Th2- cell polarization (reviewed
in [42]), with very high or low levels of TCR activation promot-
ing Th2 responses and intermediate TCR activation levels favor-
ing Th1 cell development. A recent study by van Panhuys et al.
[19] demonstrated that TCR signal strength controls downstream
cytokine receptor expression, thereby influencing the polarizing
cytokine cues received by naive Th cells during activation. How-
ever, the role of TCR signaling in Th17 cells was not assessed
within the remit of that study. We have recently shown that in
human memory T cells, a reduced signal through the TCR/CD3
complex promotes Th17 responses [23]. We therefore hypothe-
sized that post-translational modification of T-cell epitopes leading
to changes in TCR signaling strength would affect Th17 polariza-
tion of na¨ıve T cells. Our data suggest that citrullination of the
putative R93 TCR contact points leads to a decreased signaling
strength of the aggTCRtg, as demonstrated by lower prolifera-
tion, IL-2 production, and CD25 expression of responding na¨ıve
T-cells. In agreement with our hypothesis, we found that R93Cit
promoted IL-17-producing T-cells, suggesting that lowering the
affinity of pMHC–TCR complexes favors Th17 responses.
In addition to the effect of peptide-affinity on Th17 polar-
ization, we also observed a clear dose-dependent effect: at
higher, saturating peptide doses, R93Cit induced significantly
higher levels of IL-17 than the native peptide; in contrast, at
lower, suboptimal peptide concentrations IL-17 levels were more
comparable (Fig. 2). These data are in line with the notion that
the overall TCR signaling strength is determined not only by
the quality of the MHC-peptide-TCR interaction but also by the
quantity of the MHC–peptide complexes formed from the relevant
peptide epitope. However, peptide affinity and peptide density
are mutually exclusive and cannot compensate for one another
to produce the same outcome for the T-cell response, e.g. a high
dose of a low affinity peptide does not equate to a low dose
of a high affinity peptide or vice versa in terms of downstream
TCR signaling. A recent study by Gottschalk et al. [43] showed
that TCR-induced gene expression can be broadly segregated
into two groups: one that is sensitive to the cumulative TCR
signal (dependent on pMHC density) and another that responds
to the quality (affinity) of the pMHC complex, independent of
pMHC density. In particular, they found that induction of genes
involved in the IL-2 signaling pathway is more dependent on
affinity than density of pMHC complexes. Our data also support
the notion that peptide density and affinity regulate T-cell effector
development separately. Th17 polarization from na¨ıve T cells
was most efficiently promoted by a high density of a low affinity
ligand, and lowering the density of a high affinity ligand did not
result in a similar level of Th17 polarization.
Our finding that an enhancement of the pSTAT3/pSTAT5 ratio
resulted in increased Th17 responses is in line with a previous
study showing that STAT5 competes with STAT3 at multiple sites
at the IL-17 locus [39] and negatively regulates its transcription.
Thus, the relative activation of STAT3 and STAT5 determines the
propensity of na¨ıve T cells to become IL-17 producers. Our kinetics
data suggest that the pSTAT3/pSTAT5 balance early after T-cell
activation (the first 24–48 h) is critically important for Th17 cell
development. Indeed, we have previously shown that the level
of STAT3 phosphorylation during the first 24–48 h after T-cell
activation plays a critical role in determining human Th17 polar-
ization [23]. Our current study is also the first linking the strength
of the TCR signal (signal 1) to regulation of Th17 polarization via
autocrine IL-2 signaling.
An alternative way that IL-2 may regulate Th17 responses
was suggested by Liao et al. [44]; they found that IL-2 leads to
down regulation of IL-6Ra and gp130 expression, thus interfer-
ing with IL-6-induced, STAT3-mediated transcription of critical
Th17 genes. While we did not assess IL-6Ra or gp130 expres-
sion directly, STAT3 activation was comparable between both the
native and citrullinated forms of aggrecan peptide, inferring sig-
naling by IL-6 (and IL-23) was intact in our study.
We observed a sharp decrease in IL-4-producing T cells in
response to the R93Cit peptide as compared to the native peptide,
especially in the presence of pro-Th17 cytokines (Fig. 2). More-
over, blocking endogenous IL-2 in native peptide-stimulated T-cell
cultures completely abrogated the Th2 response (data not shown)
The apparent sensitivity of the Th2 response to the strength of
TCR signaling fits with the notion that IL-2-driven STAT5 signal-
ing is important for IL-4 expression by creating a permissive chro-
matin state at the il4 locus and expression of the transcription fac-
tor c-maf [45–47]. Indeed, some studies have indicated that Th2
express greater levels of CD25 and are dependent on IL-2 driven
STAT5 signaling to initiate early IL-4 production [48]. Thus, these
previous studies fit with our observation that the reduced TCR acti-
vation strength of the citrullinated peptide blocks Th2 differentia-
tion at an early stage through reduced IL-2 signaling competency.
A caveat of our study is that the TCR transgenic animal model
limits the results to the effects of peptide citrullination on a mono-
clonal T-cell population. It is unlikely that citrullination of proteins
invariably leads to the promotion of Th17 responses in polyclonal
T-cell populations, representing a diverse T-cell repertoire where
individual T-cell clones may react differently to citrullinated epi-
topes. Thus, it can be conceived that different TCRs sense the
altered, citrullinated epitope as an agonist, subagonist or even as
an antagonist. Indeed, such heterogeneity in the T-cell response
likely underlies the limited effectiveness of clinical trials testing
altered peptide ligands in multiple sclerosis patients [49, 50],
which was such a promising approach in the corresponding ani-
mal model [50, 51]. Nevertheless, despite this limitation our study
highlights the importance of the strength of TCR-mediated activa-
tion in T-cell differentiation, and provides a scenario by which a
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disease-relevant modification of an immunodominant epitope can
alter functional T-cell development.
IL-4 has been shown to suppress pathogenesis in inflamma-
tory arthritis models [52, 53]; it is, therefore interesting, that
T-cell responses were switched from protective IL-4 to pathogenic
IL-17/GM-CSF/IL-22 as a result of citrullination. It remains
to be investigated whether these type of alterations in the
Th effector cell response provide an explanation for the previously
published observations that the citrullinated form of proteins are
more arthritogenic in rodent models [27, 28], and that T cells
specific for the citrullinated form of myelin oligodendrocyte gly-
coprotein exacerbate pathology in the EAE model [54]. It should
be noted, however, that citrulline reactivity per se is not a prereq-
uisite for developing a Th17 response, as exemplified by psoriasis,
a skin disorder characterized by enrichment of Th17 cells but
not associated with the presence of ACPA [55, 56]. Nevertheless,
our data suggest that in a pro-Th17 environment, citrullination
of T-cell epitopes may further enhance the propensity of T cells
to produce Th17 cytokines, including IL-17 itself but also GM-CSF
and IL-22. Whether this mechanism is relevant to RA pathogenesis
remains to be determined, but the recent observation that ACPA
positivity in RA patients is associated with higher proportions of
Th17.1 (IL-17/IFN-γ-double producers) and Th22 cells, but not
Th1 and Th2 cells [57] provides tantalizing evidence that this is a
possible scenario.
In summary, our study demonstrates that citrullination of a
T-cell epitope can enhance Th17 responses by reducing TCR acti-
vation strength below that provided by the native epitope. Cru-
cially our results demonstrate a link between TCR activation and
the cytokine environment that can alter the response from a Th2-
to Th17-dominated response. The balance between IL-2-induced
STAT5 activation, regulated by TCR signaling, and STAT3 acti-
vation, regulated by pro-Th17 cytokines, is likely to be critical in
determining the level of Th17 polarization.
Materials and methods
Mice
5/4E8-TCR-Tg BALB/c mice are transgenic for a Vβ4/Vα1.1 TCR
specific for the immunodominant CD4 T-cell epitope of human
aggrecan, p89-103 (ATEGRVRVNSAYQDK) [34, 58]; where the
sequence is numbered 70–84). Transgenic CD4+ T cells are here-
after referred to as aggTCRtg T-cells. All work was carried out
in accordance with the Animals (Scientific Procedures) Act 1986
under the project licence PPL 60/3281 held by JHR. All animals
were housed under specific pathogen free (SPF) conditions in
Newcastle University’s Comparative Biology Centre.
Peptides
Throughout the study the following synthetic peptides were used
(core T-cell epitope highlighted); p89-103 (ATEGRVRVNSAY-
QDK), R93Cit (ATEGCitVRVNSAYQDK), R95Cit (ATEGRVCitVN-
SAYQDK), R93-95Cit (ATEGCitVCitVNSAYQDK) and the negative
control peptide F1p3 (AADLTASTTATATLVEPARI; derived from
Yersinia pestis capsular protein) not recognized by the 5/4E8 TCR
but capable of binding to Ad. All peptides were purchased from
JPT peptide technologies GmbH, Germany, >80% purity.
Cell isolation and culture
For generation of bonemarrow-derived DC (BMDC), bonemarrow
was extracted from tibias and femurs of nontransgenic littermates
and grown in RPMI-1640 (Sigma, UK); with 10% FBCS (PAA
Laboratories, UK), with 2 mM Glutamine, 100 units/mL peni-
cillin, 100μg/mL of streptomycin and 50μM β-mercaptoethanol
(all Sigma, UK) supplemented with 20 ng/mL of granulocyte-
macrophage colony-stimulating factor (GM-CSF; R&D Systems,
USA) at 2 × 106 cells/mL in 10 mL in Petri dishes. Medium supple-
mented with GM-CSF was refreshed on days 3, 6, 8, and 10 of cul-
ture. On day 10, BMDC were matured in 0.1 μg/mL lipopolysac-
charide (LPS; Sigma, UK)). After 24 h, cells were harvested
using a cell lifter. Naive CD4+CD62LhiCD44lo T-cells were isolated
by magnetic bead labelling (Miltenyi Biotech, Germany) accord-
ing to the manufacturer’s protocol. Isolations routinely yielded
>95% purity.
BMDC/T-cell co-cultures
Unless otherwise stated, 1.25 × 105 isolated naive CD4+
AggTCRtg T-cells were co-cultured with 6.25 × 103mature
BMDC (1:40 ratio of BMDCs: T cells) in IMDM (Sigma, UK);
10% serum replacement (Invitrogen); 100 units/mL penicillin;
100 μg/mL streptomycin; and 50 μM β-mercaptoethanol. Primary
culture was carried out for 5 days with peptide doses ranging
from 2 × 10−4 μM to 20 μM (2 μM if not stated otherwise)
and with or without exogenous Th17-skewing cytokines; IL-1β
(10 ng/mL; Peprotech, UK), IL-23 (10 ng/mL; Peprotech, UK),
TGF-β (10 ng/mL; R&D Systems, USA), and IL-6 (50 ng/mL;
Peprotech, UK). Proliferation was assessed by addition of
10 kBq 3H-thymidine (specific activity; 74.0 GBq/mmol; Perkin
Elmer, USA) for the last 12 h of culture. Cell DNA was harvested
onto fibreglass filter mats and radioactivity quantified by beta
scintillation spectroscopy (Perkin Elmer Microbeta TriLux; Perkin
Elmer, USA). On day 5 secondary cultures were established using
4 × 105 T cells and 2 × 103 fresh mature BMDC with 2 μM of
p89-103. Supernatants were collected after 48 h and analyzed
for cytokine levels by ELISA (see below). Alternatively, cells
were stimulated with PMA (50 ng/mL, Sigma) and ionomycin (I)
(500 ng/mL, Sigma) for 5 h at 37°C. Brefeldin A (BFA (Sigma,
UK) was added for the last 4 h. Intracellular cytokine staining
was performed as described under flow cytometry.
Enzyme-linked immunosorbant assay (ELISA)
Supernatants from co-cultures were extracted and frozen at−20°C
until required. ELISA was performed for the relevant cytokine
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according to the manufacturers’ protocols (IL-17, IL-4 and IFN-γ -
R&D Systems, USA; IL-22, and GM-CSF - eBiosciences, UK).
Flow cytometry
Cell surface and intracellular phenotypes were determined by
flow cytometry using the following reagents: anti-CD4-Alexa 488
(0.2 μg/mL, RM4-5); anti-ROR-γT-PE (2 μg/mL, Q31-378); anti-
IL-4-PE ((2 μg/mL, BVD4-1D11) BD Biosciences, UK); anti-CD25-
eFluro450 (0.2 μg/mL, eBio3C7); anti-IL-17-APC (0.2 μg/mL,
eBio17B7), anti-CD69-PE (0.2 μg/mL, H1.2F3), and anti-IFN-γ-
PEcy7 ((0.2 μg/mL, XMG1.2) eBioscience, UK). For intracellular
cytokine staining, cells were blocked with 200 μg/mL of rat serum
(Sigma, UK) and fixed and permeabilized using Foxp3 staining kit
(eBioscience) according to manufacturer’s instructions. Data were
acquired using FACS Canto-II (BD) and analyzed by Flowjo soft-
ware 8.7.1 (Treestar, USA). The following gating strategy was
used (see also Supporting Information Fig. 1: (i) a ‘life’ gate was
set on the FSC/SSC plot; (ii) a gate was set on CD4+ cells, based on
an isotype-matched control plot; (iii) marker of interest-positive
cells were gated on the basis of a fluorescence-minus-one plot
– unstained and isotype-matched control samples were used to
exclude nonspecific binding of mAbs used.
STAT3/STAT5 phosflow
Parallel co-cultures of naive T cells and BMDC were established
with 2 μM of either p89-103 or R93Cit in the presence of
pro-Th17 cytokines. These were harvested at time points between
0 and 120 h and permeabilized using appropriate buffers
(Cytofix Fixation Buffer and Perm Buffer III; BD Bioscience, UK).
Cells were incubated with 200 μg/mL of mouse serum (Sigma,
UK) for 15 min prior to the addition of antibodies. In addition
to anti-CD4-Alexa fluor 488, cells were stained using Phosflow
antibodies pSTAT3(Y705)-PE and pSTAT5(Y694)-PEcy7 (BD
Biosciences, UK) for an hour before washing and resuspension
in FACS buffer (PBS (Ca2+Mg2+ free), 0.2% BSA, 0.09%NaN3).
Data were acquired and analyzed as above.
Statistical analysis
For comparisons between two groups paired t-tests were used
to determine significance. In cases with multiple groups or time
points, p-values were determined utilizing two-way ANOVA anal-
ysis. All analyses were determined using Graphpad Prism 5.0 soft-
ware.
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